HongKong:1167

Jacobio Out-licensed KRAS G12C Inhibitor Glecirasib and SHP2 Inhibitor JAB-3312 to Allist in China

BEIJING and SHANGHAI and BOSTON, Aug. 30, 2024 /PRNewswire/ -- Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets, today announced that it has granted theChina rights (including mainland China, Hong Kong, Macau, and Taiwan) of KRAS G12C inhibitor glecirasi...

2024-08-30 19:34 5624

Jacobio Pharma Presents SHP2 Plus KRAS G12C Data at ASCO

BEIJING and SHANGHAI and CHICAGO, June 1, 2024 /PRNewswire/ -- Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets, presented updated data of a KRAS G12C inhibitor glecirasib (JAB-21822) in combination with aSHP2 inhibitor (JAB-3312) in frontline non-small ...

2024-06-02 08:25 3528

Jacobio Pharma Announced its KRAS G12C inhibitor reached the primary endpoint

BEIJING and SHANGHAI and BOSTON, April 30, 2024 /PRNewswire/ -- Jacobio Pharma (1167.HK) announced that the data from the Phase II registrational study of the KRAS G12C inhibitor glecirasib were offically reported at the April ASCO Plenary Series, which was held online. Prof. Yuankai Shi, chief ...

2024-05-01 08:59 1460

Jacobio Pharma to Present Data of PARP7 Inhibitor and P53 Reactivator at the 2024 AACR Annual Meeting

BEIJING, SHANGHAI, and SAN DIEGO, April 9, 2024 /PRNewswire/ -- Jacobin Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets, today announced that the company will present the results of two preclinical evaluation of PARP7 inhibitor JAB-26766 and p53 Y220C reactivat...

2024-04-09 19:59 1341

Jacobio Pharma Announces 2023 Annual Results

BEIJING, SHANGHAI and BOSTON, March 28, 2024 Jacobio/PRNewswire/ --  Pharma (1167.HK), a clinical-stage oncology company drugging the undruggable targets, today announced its 2023 annual results. The revenue wasRMB63.5 million, the R&D investment wasRMB372 million, the cash and cash equivalent at...

2024-03-29 08:50 4413

Jacobio Pharma Receives IND Approval for P53 Y220C Activator JAB-30300 in the U.S.

BEIJING, SHANGHAI and BOSTON, March 1, 2024 /PRNewswire/ -- Jacobio Pharma (1167.HK), a clinical-stage oncology company drugging the undruggable targets, today announced it received IND (Investigational New Drug) approval of its self-developed drug JAB-30300 (P53 Y220C activator) from the FDA of ...

2024-03-01 14:55 2392

Jacobio Announces China CDE Clearance for Phase III Clinical Trial of SHP2 Inhibitor Plus KRAS G12C Inhibitor

BEIJING and SHANGHAI and BOSTON, Feb. 18, 2024 /PRNewswire/ -- Jacobio Pharma (1167.HK), a clinical-stage oncology company drugging the undruggable targets, today announced it received approval of registrational phase III clinical trial of the combination therapy between its novel KRAS G12C inhib...

2024-02-18 20:50 2541

Jacobio Pharma Presents Data of Glecirasib in Patients with Pancreatic Cancer and Other Solid Tumors at the 2024 ASCO GI

BEIJING and SAN FRANCISCO, Jan. 19, 2024 /PRNewswire/ -- Jacobio Pharmaceuticals (1167.HK), a clinical-stage oncology company focusing on undruggable targets, announced data of glecirasib in patients with pancreatic cancer and other solid tumors in the oral abstract session at the American Socie...

2024-01-20 06:30 2702

Jacobio Pharma Presents Clinical Results of Glecirasib in Combination with JAB-3312 at ESMO

* The ORR (objective response rate) and the DCR (disease control rate) in the frontline setting of glecirasib (KRAS G12C Inhibitor) in combination with JAB-3312 (SHP2 inhibitor) were 65.5% (38/58) and 100% respectively in all dose groups of advanced non-small cell lung cancer (NSCLC), among whi...

2023-10-22 15:05 2054

Jacobio Pharma Announces 2023 Interim Results

BEIJING, SHANGHAI and BOSTON, Aug. 30, 2023 /PRNewswire/ -- Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets, announced its 2023 interim results. During the period, the company recorded revenue ofRMB 40.3 million even as it continued to accelerate multip...

2023-08-30 21:45 3843

Jacobio Pharma Announces Breakthrough Therapy Designation from China CDE for KRAS G12C Inhibitor Glecirasib for the Treatment of Pancreatic Cancer

BEIJING, SHANGHAI and BOSTON, Aug. 7, 2023 /PRNewswire/ -- Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets, today announced that Jacobio's in-house KRAS G12C inhibitor glecirasib was granted breakthrough therapy designation (BTD) by the Center for Drug ...

2023-08-07 20:03 2137

Jacobio Pharma to Present Data of Glecirasib in Combination with JAB-3312 at the 2023 ESMO Conference

BEIJING and SHANGHAI and BOSTON, July 20, 2023 /PRNewswire/ -- Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets, is pleased to announce today that the company will present its clinical results in the form of Proffered Paper presentation at the 2023 Europ...

2023-07-21 10:19 1897

Jacobio Receives CDE Approval for Glecirasib's Pancreatic Cancer Pivotal Study in China

BEIJING, SHANGHAI and BOSTON, July 4, 2023 /PRNewswire/ -- Jacobio Pharma (1167.HK), a clinical-stage oncology company drugging the undruggable targets, today announced its novel KRAS G12C inhibitor glecirasib's pivotal study for pancreatic cancer has been approved from CDE (Center for Drug Evalu...

2023-07-04 21:16 2353

Jacobio Pharma Presents Clinical Results of Glecirasib in Colorectal Cancer

BEIJING, KYOTO and BOSTON, June 29, 2023 /PRNewswire/ -- Jacobio Pharma (1167.HK), a clinical-stage oncology company drugging the undruggable targets, today announced clinical results of its novel KRAS G12C inhibitor glecirasib monotherapy and in combination therapy with cetuximab to treat KRAS G...

2023-06-29 16:31 1877

Jacobio Pharma Announces 2022 Annual Results

BEIJING, SHANGHAI and BOSTON, March 22, 2023 /PRNewswire/ -- Jacobio Pharma (1167.HK) announced its 2022 annual results. R&D investment wasRMB530 million, showing an increase of 26% compared with 2021. The revenue wasRMB95.7 million, which was generated from an out-licensing deal. Jacobio Pharma ...

2023-03-22 22:38 3266

Jacobio announces clinical collaboration to evaluate CD73 monoclonal antibody JAB-BX102 in combination with KEYTRUDA® (pembrolizumab) for patients with cancer

BEIJING, SHANGHAI and BOSTON, March 22, 2023 /PRNewswire/ -- Jacobio Pharma (1167.HK) announced it has entered into a clinical collaboration with Merck & Co., Inc.,Rahway, NJ, USA to evaluate the combination of Jacobio's CD73 monoclonal antibody JAB-BX102 in combination with Merck & Co., Inc., Ra...

2023-03-22 12:36 2020

Jacobio Pharma to Present Data of Three Preclinical Studies at the 2023 AACR Annual Meeting

BEIJING and SHANGHAI and BOSTON, Mass., March 14, 2023 /PRNewswire/ -- Jacobin Pharma (1167.HK) today announced that the company will present the results of three preclinical studies of KRASmulti inhibitor JAB-23425, CD73-STING iADC JAB-X1800, and Aurora kinase A inhibitor JAB-2485 in form of the...

2023-03-15 10:45 3024

Jacobio Completes First Patient Dosage of Aurora A Inhibitor JAB-2485 in U.S

BEIJING and SHANGHAI and BOSTON, Jan. 8, 2023 /PRNewswire/ -- Jacobio Pharma (1167.HK) announced it has completedthe first patient dosage of its in-house R&D drug candidate Aurora A Inhibitor JAB-2485 in a Phase I/IIa clinical trial for advanced solid tumour patients in U.S. JAB-2485 is a high...

2023-01-08 14:17 3408

Jacobio's KRAS G12C Inhibitor JAB-21822 was Granted Breakthrough Therapy Designations by China CDE

BEIJING, SHANGHAI and BOSTON, Dec. 15, 2022 /PRNewswire/ -- Jacobio Pharma (1167. HK) announced that the Company's in-house KRAS G12C inhibitor JAB-21822 was granted breakthrough therapy designations for the second line and above treatment of advanced or metastatic non-small cell lung cancer (NSC...

2022-12-16 08:42 2637

Jacobio's Preclinical Results of KRAS G12C Inhibitor in Combination with SHP2 Inhibitor Will be Presented at the ESMO Asia Congress 2022

BEIJING, SHANGHAI and BOSTON, Dec. 1, 2022 /PRNewswire/ -- Jacobio Pharma (1167.HK) will present the results of KRAS G12C inhibitor JAB-21822 as a single agent or in combination withSHP2 inhibitor JAB-3312 in preclinical cancer models in a poster session during the 2022 European Society of Medica...

2022-12-02 08:30 1509
12